ライフサイエンスコーパス: fibrotic

1 Trabeculectomy with anti-fibrotics (14 eyes) showed 57% success with 16.5 +/- 13.

2 n, an angiotensin-receptor blocker with anti-fibrotic abilities, recapitulates the effect of exercise

3 um, with variable levels of inflammatory and fibrotic activity, although all subtypes are regarded as

4 histological hallmarks of contracture (e.g., fibrotic adhesions and reduced joint space) are absent i

5 ificant predictor of mortality and many anti-fibrotic agents are under evaluation.

6 HP can be classified into acute, chronic non-fibrotic and chronic fibrotic forms.

7 l Crohn's disease presenting with 3 severely fibrotic and deformed bowel loops separated by 2 disease

8 ormed in patients presenting with 3 severely fibrotic and deformed bowel loops separated by 2 disease

9 HF with reduced ejection fraction were more fibrotic and elastic than myocardium from patients with

10 TGFbetaRII deletion resulted in larger, more fibrotic and higher vascularized venous thrombi.

11 lastic tumor microenvironment that is highly fibrotic and immune suppressive.

12 ls of liver fibrosis and lower expression of fibrotic and inflammatory biomarkers.

13 FLCs mediate renal injury in MM by inducing fibrotic and inflammatory pathways in the kidney.

14 ights and potential targets for a variety of fibrotic and malignant diseases.

15 We demonstrate application to inflammatory, fibrotic and neoplastic disease in multiple organs, incl

16 clude perturbations of pro-inflammatory, pro-fibrotic and oxidative stress markers, sometimes togethe

17 RNA sequencing characterized CrF as both pro-fibrotic and pro-adipogenic with a rich milieu of activa

18 associated secretory phenotype, which is pro-fibrotic and pro-hypertrophic.

19 s that drive these functionally opposing pro-fibrotic and pro-inflammatory phenotypes of fibroblasts

20 diabetic PTECs, signified by deregulation of fibrotic and transport-associated genes (TAGs).

21 Trabeculectomy with anti-fibrotics and Baerveldt glaucoma drainage devices showed

22 Relative levels of extracellular matrix, fibrotic, and inflammatory cell content were comparable

23 es of human breast cancers tend to be highly fibrotic, and unlike primary breast tumors, they exclude

24 cs), cycloablation, trabeculectomy with anti-fibrotics, and glaucoma drainage device placement were a

25 Providing the anti-fibrotic angiotensin receptor blocker losartan to mice i

26 The fibrotic areas mainly consist of type I collagen extrace

27 The fibrotic areas mainly consisted of type I collagen with

28 ed the RDs were much smaller than the entire fibrotic areas, indicating potential targets for ablatio

29 Formula: see text] T cells can cross typical fibrotic barriers and thus their infiltration into tumor

30 ifficult locations or those with a rigid and fibrotic base.

31 ction with Chlamydia trachomatis may lead to fibrotic blockage in women's upper genital tracts, resul

32 noculation with C. muridarum readily induces fibrotic blockage or hydrosalpinx in mice and is used fo

33 astrointestinal tract while inducing oviduct fibrotic blockage or hydrosalpinx.

34 denosis, chronic inflammation, fat necrosis, fibrotic breast tissue, and scar tissue, were as high as

35 efine BRD4 as a central regulator of the pro-fibrotic cardiac fibroblast phenotype, establish a p38-d

36 Despite its established significance in fibrotic cardiac remodeling, clinical benefits of global

37 the phosphoproteomic profiling of normal and fibrotic cardiac tissue obtained from surgical explants

38 that CXCR2 inhibition promotes activation of fibrotic cells (myofibroblasts) and impact tumors in a m

39 r dystrophies, it has been hypothesized that fibrotic changes in skeletal muscle are irreversible.

40 olume of collagen orientation, characterizes fibrotic changes independently from the depth of the reg

41 ying cause of the condition: accumulation of fibrotic collagenous tissue.

42 nisms governing the interactions between the fibrotic components and their modifiers remain largely u

43 /-) female mice were characterized by a more fibrotic composition due to a reduction in inflammation,

44 e use this assay to test the potency of anti-fibrotic compounds and screen siRNAs for regulators of T

45 ways driving fibrosis and to screen for anti-fibrotic compounds targeting glycogen synthase kinase 3,

46 tients with Dupuytren's disease, a localized fibrotic condition of the hand.

47 The underlying pathology of all fibrotic conditions is the activity of myofibroblasts.

48 oblasts are key contributors to pathological fibrotic conditions of several major organs.

49 extracellular matrix deposition in multiple fibrotic conditions, including idiopathic pulmonary fibr

50 n of FOXF1 mRNA and protein, compared to non-fibrotic controls.

51 Results AUC for distinguishing fibrotic (CPA >4.8%) from nonfibrotic (CPA <=4.8%) liver

52 ion signature, providing evidence that a pro-fibrotic cytokine environment can influence the proximo-

53 -relevant cocktail (IPF-RC) to mimic the pro-fibrotic cytokine milieu present in IPF lungs.

54 Treatment of mucosa with Th2 and fibrotic cytokines recapitulated the majority of the cli

55 ial cells, resulting in the secretion of pro-fibrotic cytokines, thereby promoting interstitial fibro

56 esses that regulate glutamine metabolism and fibrotic development in a TGF-beta-dependent manner.

57 creatitis (CP) is a chronic inflammatory and fibrotic disease of the pancreas with a prevalence of 42

58 ught to identify new therapeutic targets for fibrotic disease.

59 vestigation into myeloid cells as drivers of fibrotic disease.

60 omplex biological mechanisms responsible for fibrotic diseases and developing effective therapies.

61 eutic intervention in human inflammatory and fibrotic diseases is also discussed.

62 the persistent activity of myofibroblasts in fibrotic diseases might involve epigenetic modifications

63 Fibrotic diseases remain a major cause of morbidity and

64 destructive tissue remodeling that occurs in fibrotic diseases such as TED.

65 In fibrotic diseases, fibroblasts synthesize abundant amoun

66 Pathogenic fibrotic diseases, including idiopathic pulmonary fibros

67 n of PU.1 expression is perturbed in various fibrotic diseases, resulting in the upregulation of PU.1

68 f UCHL1 as a potential therapeutic target in fibrotic diseases.

69 the potential for application against other fibrotic diseases.

70 diovascular, neurological, inflammatory, and fibrotic diseases.

71 lopment of targeted therapies for individual fibrotic diseases.

72 athophysiological relevance across different fibrotic diseases.

73 for intimal hyperplasia, wound healing, and fibrotic diseases.

74 o prevent and treat several inflammatory and fibrotic diseases.

75 rapeutic approach in inflammatory as well as fibrotic diseases.

76 ed receptor associated with inflammatory and fibrotic diseases.

77 s with Dupuytren's disease (DD), a localized fibrotic disorder of the palm, we sought to identify new

78 CDH11, which has been associated with other fibrotic disorders and is expressed by activated fibrobl

79 Fibrotic disorders are some of the most devastating and

80 g development and the rare incidence of many fibrotic disorders hinder the development of targeted th

81 e (corpora cavernosa) fibrosis are localized fibrotic disorders of the penile connective tissues that

82 ent or progression of cancer, wound healing, fibrotic disorders, and immune modulation, to name a few

83 actable therapeutic target across a range of fibrotic disorders.

84 Further, treatment with the anti-fibrotic drug pirfenidone reduced pulmonary fibrosis in

85 rest, pirfenidone (Pf), an FDA approved anti-fibrotic drug to treat idiopathic pulmonary fibrosis, ha

86 f aged macrophages with pirfenidone, an anti-fibrotic drug with antioxidant and anti-inflammatory pro

87 used in the preclinical testing of new anti-fibrotic drugs, a thorough validation of micro-computed

88 nisms of cardiac fibrosis and to screen anti-fibrotic drugs.

89 nical network that allows HSCs to maintain a fibrotic ECM, with external rigidity providing feedback

90 Its anti-fibrotic effect has been confirmed in experimental and c

91 Besides its anti-fibrotic effect, FZHY ameliorated CCl(4) and DMN-induced

92 Drugs with anti-inflammatory and anti-fibrotic effects are of promise for improving healing by

93 lthough various FXR agonists have shown anti-fibrotic effects in diverse preclinical animal models, t

94 onary note on the potential deleterious, pro-fibrotic effects of exogenous MSCs once intravitreally i

95 st activation and partially antagonizes anti-fibrotic effects of halofuginone treatment.

96 We elucidated the anti-fibrotic effects of neratinib in hepatic stellate cells

97 Moreover, the anti-fibrotic effects of neratinib were not associated with t

98 Synergistic pro-fibrotic effects of TGF-beta were observed across GCs an

99 usly reported dexamethasone enhanced the pro-fibrotic effects of transforming growth factor (TGF)-bet

100 nstrated profound anti-inflammatory and anti-fibrotic efficiency in a kidney injury model caused by u

101 e tissue growth factor (CTGF) aggravates the fibrotic environment and drives cancer initiation and pr

102 C (IFP-MSC) reaction to inflammatory and pro-fibrotic environments (cell priming by TNFalpha/IFNgamma

103 lose to half of all reported deaths having a fibrotic etiology.

104 essential for SAN conduction, especially in fibrotic failing hearts.

105 elucidate the specific mechanisms supporting fibrotic feed-forward loops.

106 We show that JUN is activated in fibrotic fibroblasts that expressed increased CD47 and P

107 switch in extracellular matrix-producing pro-fibrotic fibroblasts.

108 n within Dupuytren's nodules and also in the fibrotic foci of idiopathic pulmonary fibrosis (IPF).

109 at could be used alongside conventional anti-fibrotics for pulmonary fibrosis.

110 into acute, chronic non-fibrotic and chronic fibrotic forms.

111 or PU.1 as an essential regulator of the pro-fibrotic gene expression program.

112 gron treatment stimulated lipolysis, reduced fibrotic gene expression, and increased alternatively ac

113 Importantly, the WWP2-regulated pro-fibrotic gene network is conserved across different card

114 ERPINE1, a critical pro-inflammatory and pro-fibrotic gene.

115 issue Tetranectin correlated positively with fibrotic genes and protein within the myocardium.

116 owed changes in transcript levels of several fibrotic genes, including TGFbeta2, BAMBI, and SMA.

117 tion and the activation of TGF-beta1-induced fibrotic genes.

118 Mice with a fibrotic HCC were treated with the IRE1alpha-inhibitor 4

119 activities that distinguish regenerative vs fibrotic healing.

120 Some patients with fibrotic HP may evolve to a progressive phenotype, even

121 For patients with fibrotic HP, suggestions were made in favor of obtaining

122 l mechanisms are also active in the diseased fibrotic human heart.

123 imal and non-proximal tubules of healthy and fibrotic human kidneys to map the entire human kidney.

124 Fibrotic human LR-MSCs demonstrated lower expression of

125 Finally, fibrotic human lungs demonstrate altered BMP activation

126 l carcinoma (SCC), even though the stroma is fibrotic in both histotypes.

127 duced sarcolemmal weakening, muscle tearing, fibrotic infiltration and rounds of degeneration and fai

128 ions that obstruct proximal ducts leading to fibrotic injury and ultimately pancreatic insufficiency

129 ry mediators of immune cell infiltration and fibrotic injury in livers of obese mice.

130 sex-biased and shared molecular responses to fibrotic injury, including up- and downregulated long no

131 (ApoM) protects the lung and kidney from pro-fibrotic insults and that this circulating factor is att

132 tilator characteristics of a large cohort of fibrotic interstitial lung disease patients from the per

133 rior studies report significant mortality in fibrotic interstitial lung disease patients undergoing m

134 ral factors predict in-hospital mortality in fibrotic interstitial lung disease-associated mechanical

135 teric adipose tissue around the inflamed and fibrotic intestine.

136 hat OASIS protein was overexpressed in human fibrotic kidney compared with normal kidney.

137 nses, and successful performance on inflamed fibrotic kidney.

138 450 nm), relative to longer wavelengths, for fibrotic kidneys compared to normal kidney, with a quasi

139 oform expression was robustly induced in the fibrotic kidneys of mice and humans.

140 Moreover, OASIS was upregulated in murine fibrotic kidneys, following unilateral ureteral obstruct

141 Hepatocyte, fibrotic lesion, and bile duct (cancer) were classified

142 g MI coupled with a reduced infarct size and fibrotic lesion.

143 tolerated, reduced the severity of pulmonary fibrotic lesions and extracellular matrix remodeling, an

144 In fibrotic lesions, spatially restricted generation of bio

145 plaque morphology and was the highest among fibrotic lesions.

146 hey underwent fate change from adipogenic to fibrotic lineage.

147 Fibrotic liver tissues from patients and rodents (mice a

148 Levels of PFKFB3 protein were increased in fibrotic liver tissues from patients compared with non-f

149 iver tissues from patients compared with non-fibrotic liver.

150 es an attractive target for the treatment of fibrotic lung diseases.

151 prove useful in preventing alloimmune-driven fibrotic lung diseases.

152 n cause that is characterized by progressive fibrotic lung remodeling.

153 n of IGF-1 via TGFbeta in myofibroblasts and fibrotic lung tissue, as well as its correlation with de

154 gulated in select injured tissues, including fibrotic lung.

155 riple helix repeat containing 1), emerges in fibrotic lungs and expresses the highest levels of colla

156 perplastic basal cells and myofibroblasts of fibrotic lungs from patients with idiopathic pulmonary f

157 e uptake of (68)Ga-NODAGA-indole in actively fibrotic lungs is 7-fold higher than in control groups a

158 as observed after bleomycin treatment and in fibrotic lungs of prospero homeobox 1-enhanced green flu

159 ly, accumulation of PATS-like cells in human fibrotic lungs was observed, suggesting persistence of t

160 y all collagen-producing cells in normal and fibrotic lungs.

161 1-expressing fibroblasts present uniquely in fibrotic lungs.

162 2 positively regulates the expression of pro-fibrotic markers and extracellular matrix genes.

163 uorescence staining of capsular bags for the fibrotic markers f-actin, fibronectin, alpha smooth musc

164 The fibrotic markers f-actin, fibronectin, alpha smooth musc

165 of HDAC8, and increased expression of three fibrotic markers: alpha-smooth muscle actin, collagen 1,

166 normal stromal matrix and is replaced with a fibrotic matrix structure.

167 ology confirmed MR-based vessel features and fibrotic measurements.

168 Acute tendon injuries often heal through a fibrotic mechanism, which impedes regeneration and funct

169 sforming growth factor-beta (TGFbeta), a pro-fibrotic mediator that is pivotal to the development of

170 in the progression of HCC, as they create a fibrotic micro-environment and produce growth factors an

171 PTECs under hypoxic conditions (modeling the fibrotic microenvironment) displayed significantly upreg

172 Tumor stroma resembles a fibrotic microenvironment, being characterized by the pr

173 echanical and growth factor signals from the fibrotic microenvironment, which can ultimately lead to

174 f microRNA (miRNA) function on targeting the fibrotic microenvironment.

175 tion is a limited understanding of the human fibrotic microenvironment.

176 A molecular taxonomy of the fibrotic milieu characterises functionally distinct stro

177 ed to TL1A by proliferating and/or producing fibrotic molecules such as collagen and periostin.

178 cell shape occur, leading to a more spread, fibrotic morphology associated with stronger F-actin ali

179 array data from diseased patient kidneys and fibrotic mouse model kidneys both exhibit OASIS/Creb3l1

180 omparison of gray-scale values in normal and fibrotic myocardium.

181 Ten inactive fibrotic nodules, identical to end-stage de novo lesions

182 ation and subsequently evolved into unifocal fibrotic nodules.

183 urden below 25%, RDs either moved near small fibrotic patches or anchored to anatomical features.

184 Ds anchored to specific locations near large fibrotic patches.

185 s and Prevotella, were identified to promote fibrotic pathogenesis through IL-17R signaling.

186 ually transmitted Chlamydia, which can cause fibrotic pathology in women's genital tracts, is also fr

187 the final common pathological step along the fibrotic pathway in CKD.

188 studies targeting plasma cell clones and/or fibrotic pathways are warranted for long-term scleromyxe

189 ok at the immune, inflammatory, vascular and fibrotic pathways implicated in the pathogenesis of SSc,

190 monitor and quantify dysregulated molecular fibrotic pathways in a noninvasive manner.

191 MicroRNAs that regulate ER and fibrotic pathways were assessed.

192 nhancing our understanding of HIV-associated fibrotic pathways will remain important for new diagnost

193 ed that Bic initiated multiple apoptotic and fibrotic pathways, including androgen deprivation, downr

194 qRT-PCR analysis of RV confirmed effects on fibrotic pathways.

195 ent to induce inflammatory, late repair, and fibrotic pathways.

196 and Alk5i blunted progression of fibrosis in fibrotic PCLS.

197 g time during islet isolation of younger and fibrotic pediatric pancreases, gave increased islet yiel

198 TGFbeta1/SMAD2 activation, and reduced their fibrotic phenotype and antitumor responses to nintedanib

199 ce of circadian mechanisms in the underlying fibrotic phenotype is not understood.

200 The fibrotic phenotype is thought to be regulated by changes

201 hat nintedanib inhibited the tumor-promoting fibrotic phenotype of TAFs selectively in ADC.

202 -derived stem cell (ASC) transition to a pro-fibrotic phenotype, expanding their regenerative potenti

203 short-term apoptosis and the emergence of a fibrotic phenotype.

204 We previously showed that GO adipogenic and fibrotic phenotypes could be modelled in a pseudo-physio

205 HP was classified into nonfibrotic and fibrotic phenotypes.

206 NR4A1 upregulation consistent with the anti-fibrotic potential of GCs.

207 rstanding and treatment for reversing of the fibrotic process is limited in systemic sclerosis (SSc).

208 IT cells in the kidney may contribute to the fibrotic process of CKD via complex interactions with PT

209 is; elucidation of these early events in the fibrotic process will provide targets for treatment of h

210 promising HF biomarker candidate linked with fibrotic processes within the myocardium.

211 ed inflammation and reversed the exacerbated fibrotic profile of Map3k8 (-/-) mice.

212 ng may facilitate myofibroblast survival and fibrotic progression.

213 h both cell populations being key drivers of fibrotic progression.

214 Endothelial and fibrotic protein expression level are associated with re

215 ome is seen almost exclusively in those with fibrotic pulmonary sarcoidosis, which accounts for 10% t

216 joint pathologic conditions, it exacerbates fibrotic RA-ILD.

217 o sustain inflammasome activation and worsen fibrotic reactions.

218 explore the dynamics of RD stabilization in fibrotic regions and generate maps of RD locations.

219 the atypical epithelial cells of the distal fibrotic regions.

220 that ultimately converge to drive downstream fibrotic remodeling in the IPF lung.

221 to regulate AEC2 cell injury and subsequent fibrotic remodeling in the lung.

222 lung congestion, and prevented apoptosis and fibrotic remodeling in transverse aortic constriction.

223 ulation of TGFbeta signaling, which promotes fibrotic remodeling.

224 epithelial abnormalities, and subepithelial fibrotic remodeling.

225 The polarization mediated fibrotic repair in the absence of injury by enhancing ma

226 During fibrotic repair, Gli1(+) MSCs integrate hedgehog activat

227 gate the role of macrophages in dysregulated fibrotic repair.

228 nical roles for macrophages in mediating the fibrotic response after a heart attack include extracell

229 e the mechanism(s) whereby GCs influence the fibrotic response and mechanisms underlying these effect

230 d, and the cell types that contribute to the fibrotic response are incompletely defined.

231 on of the gland showed an aberrant sustained fibrotic response characterized by increased levels of E

232 iary dysfunction and aberrant epithelial pro-fibrotic response in the multifactorial disease pathogen

233 oid-specific deletion of Tgfb1 abrogates the fibrotic response in this injury model and reduces fibro

234 subpopulations of macrophages in promoting a fibrotic response is an emerging target.

235 on and inflammation but no difference in the fibrotic response of IPF fibroblasts.

236 mental approaches whose aim is to reduce the fibrotic response that the typical mammal displays in re

237 ne a normal healing response and an aberrant fibrotic response within the same gland to uncover mecha

238 mune system, the tumor microenvironment, the fibrotic response, and stem cell function.

239 ssion of the involved genes and mitigate the fibrotic response, confirming a key role for p53 in rena

240 Genes involved in the fibrotic response, including ACTA2, TGFBR1, and TGFBR2 w

241 psulated with CXCL12 evaded the pericapsular fibrotic response, resulting in long-term functional com

242 d IPF fibroblasts but had no effect upon the fibrotic response.

243 alization and reductions in inflammation and fibrotic response.

244 ells) and/or myofibroblasts to mimic in vivo fibrotic responses and dynamics.

245 dothelial SHIP-1 is essential in controlling fibrotic responses and SHIP-1 is a target of miR-155.

246 ng a major role for macrophages in pulmonary fibrotic responses and suggesting a main role for Map3k8

247 ent and selective UCHL1 inhibitors block pro-fibrotic responses in a cellular model of idiopathic pul

248 othelial-mesenchymal transition (EndoMT) and fibrotic responses in bleomycin (BLM) induced lung fibro

249 dothelial miR-155 plays an important role in fibrotic responses in the lung through EndoMT.

250 d in TGF-beta1 or BLM, respectively, induced fibrotic responses.

251 ithout altering ligand density, we show that fibrotic rigidities downregulate MMP-9 expression and se

252 atrophy (GA, n = 25), non-GA (NGA, n = 44), fibrotic scar (FS, n = 26), or non-FS (NFS, n = 7).

253 ective therapeutic to prevent formation of a fibrotic scar (hypertrophic scar or keloid) or to preven

254 ation and angiogenesis and may contribute to fibrotic scar formation.

255 unique mechanism of anti-inflammation-based fibrotic scar reduction.

256 and the lost cells are primarily replaced by fibrotic scar tissue.

257 d no significant differences in lesion size, fibrotic scar, gliosis or neuroinflammation between grou

258 of function due to the formation of a glial-fibrotic scar.

259 s paper presents a morphological analysis of fibrotic scarring in non-ischemic dilated cardiomyopathy

260 Adhesions are fibrotic scars that form between abdominal organs follow

261 , which worsens the pro-inflammatory and pro-fibrotic shift observed in nonalcoholic steatohepatitis.

262 f myofibroblasts and early activation of pro-fibrotic signaling pathways before adverse ventricular r

263 -beta activities to balance regenerative and fibrotic signals.

264 Moreover, a high IFN-response signature and fibrotic signature in tubular cells were each associated

265 AFLD can range in severity from steatosis to fibrotic steatohepatitis and is a major cause of hepatic

266 vascular congestion and inflammatory and pro-fibrotic stimuli, and is a strong, independent predictor

267 A fumigatus, in order to propose novel anti-fibrotic strategies for fungal-induced asthma.

268 rowing of the cecum-a feature reminiscent of fibrotic strictures seen in Crohn disease patients.

269 The tumor-promoting fibrotic stroma rich in tumor-associated fibroblasts (TA

270 Nckap1-depleted tumors displayed fibrotic stroma with increased collagen deposition conco

271 breast cancers are characterized by a dense fibrotic stroma, which is considered immunosuppressive i

272 and our knowledge of IGF-1's role as a novel fibrotic-switch, bringing us one step closer to understa

273 were previously proposed as therapeutic anti-fibrotic target, and ITGA5, that has been less studied i

274 egulation of several pro-atherogenic and pro-fibrotic targets including ICAM-1 and the connective tis

275 ata suggest that NF-kappaB may contribute to fibrotic tendon healing through both inflammation-depend

276 Pro-inflammatory (TNF-alpha, IL-6) and pro-fibrotic (TGF-beta1) cytokines were significantly increa

277 in human IPF lung and reduces downstream pro-fibrotic TGFbeta signaling to normal levels.

278 Effective anti-fibrotic therapeutic solutions, however, are not availab

279 Fibrotic therapies are potentially relevant to numerous

280 elopment of BRD4 inhibitors as targeted anti-fibrotic therapies for the heart.

281 project may guide development of novel anti-fibrotic therapies in a network pharmacology approach.

282 y additionally aid in the monitoring of anti-fibrotic therapies in clinical practice.

283 e potential of inhaled GSK3008348 as an anti-fibrotic therapy.

284 KLHL42 knockdown reduced fibrotic tissue production and decreased TGF-beta-mediat

285 ts leukocyte infiltration, inflammation, and fibrotic tissue remodeling after renal IRI, thus prevent

286 of pancreatic inflammation lead to extensive fibrotic tissue replacement, resulting in chronic pain,

287 e significantly increased on MAIT cells from fibrotic tissue samples.

288 al model of the atria of patients identifies fibrotic tissue that, if ablated, will not sustain AF.

289 itude and lack of synchrony within pulmonary fibrotic tissue.

290 characterized by the abundant deposition of fibrotic tissue.

291 ently upregulated in a wide variety of human fibrotic tissues and diseases and was strongly induced b

292 significantly decreased in activated HSCs in fibrotic tissues associated with hepatocellular carcinom

293 ferent distributions, sizes and positions of fibrotic tissues contribute to arrhythmogenesis.

294 nisms that help myofibroblasts to persist in fibrotic tissues remain poorly understood.

295 critical for cell activation in inflamed and fibrotic tissues; however, the cytoskeleton has not been

296 h treatment are due to an immunosuppressive, fibrotic tumor microenvironment that prevents drugs from

297 de of this differentiation step with an anti-fibrotic tyrosine kinase inhibitor decreases post-myocar

298 GLS1 was found to be highly expressed in fibrotic vs normal lung fibroblasts and the expression o

299 rix that dehydrates and becomes increasingly fibrotic with age.

300 tivate this developmental program results in fibrotic wound healing.